132 related articles for article (PubMed ID: 36126509)
1. Correlation of pituitary histomorphometry with dopamine and dopamine D2 receptor expression in horses with pituitary pars intermedia dysfunction.
Huang L; Palmieri C; Bertin FR
Res Vet Sci; 2022 Dec; 152():427-433. PubMed ID: 36126509
[TBL] [Abstract][Full Text] [Related]
2. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
[TBL] [Abstract][Full Text] [Related]
3. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.
Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE
Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571
[TBL] [Abstract][Full Text] [Related]
4. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.
McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE
J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757
[TBL] [Abstract][Full Text] [Related]
5. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction.
McFarlane D; Holbrook TC
J Vet Intern Med; 2008; 22(2):436-42. PubMed ID: 18371032
[TBL] [Abstract][Full Text] [Related]
6. Effects of advanced age and pituitary pars intermedia dysfunction on components of the acute phase reaction in horses.
Zak A; Siwinska N; Elzinga S; Barker VD; Stefaniak T; Schanbacher BJ; Place NJ; Niedzwiedz A; Adams AA
Domest Anim Endocrinol; 2020 Jul; 72():106476. PubMed ID: 32380311
[TBL] [Abstract][Full Text] [Related]
7. Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy.
Fortin JS; Hetak AA; Duggan KE; Burglass CM; Penticoff HB; Schott HC
Sci Rep; 2021 Aug; 11(1):16036. PubMed ID: 34362943
[TBL] [Abstract][Full Text] [Related]
8. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
[TBL] [Abstract][Full Text] [Related]
9. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
Rendle DI; Litchfield E; Heller J; Hughes KJ
Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
[TBL] [Abstract][Full Text] [Related]
10. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
Copas VE; Durham AE
Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
[TBL] [Abstract][Full Text] [Related]
11. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.
McFarlane D
Ageing Res Rev; 2007 May; 6(1):54-63. PubMed ID: 17374512
[TBL] [Abstract][Full Text] [Related]
12. Profiles of pro-opiomelanocortin and encoded peptides, and their processing enzymes in equine pituitary pars intermedia dysfunction.
Carmalt JL; Mortazavi S; McOnie RC; Allen AL; Unniappan S
PLoS One; 2018; 13(1):e0190796. PubMed ID: 29309431
[TBL] [Abstract][Full Text] [Related]
13. Relationships of inflamm-aging with circulating nutrient levels, body composition, age, and pituitary pars intermedia dysfunction in a senior horse population.
Siard-Altman MH; Harris PA; Moffett-Krotky AD; Ireland JL; Betancourt A; Barker VD; McMurry KE; Reedy SE; Adams AA
Vet Immunol Immunopathol; 2020 Mar; 221():110013. PubMed ID: 32058159
[TBL] [Abstract][Full Text] [Related]
14. Perianesthetic development of diaphragmatic hernia in a horse with equine pituitary pars intermedia dysfunction (PPID).
Shepard MK; Lee WL; Eggleston RB
Can Vet J; 2015 Jan; 56(1):48-52. PubMed ID: 25565714
[TBL] [Abstract][Full Text] [Related]
15. Assessment of tissue-specific cortisol activity with regard to degeneration of the suspensory ligaments in horses with pituitary pars intermedia dysfunction.
Hofberger SC; Gauff F; Thaller D; Morgan R; Keen JA; Licka TF
Am J Vet Res; 2018 Feb; 79(2):199-210. PubMed ID: 29359976
[TBL] [Abstract][Full Text] [Related]
16. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
17. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
Rendle DI; Duz M; Beech J; Parkin T; Durham AE
J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
[TBL] [Abstract][Full Text] [Related]
18. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction.
Pease AP; Schott HC; Howey EB; Patterson JS
J Vet Intern Med; 2011; 25(5):1144-51. PubMed ID: 21985144
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
[TBL] [Abstract][Full Text] [Related]
20. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.
McFarlane D; Cribb AE
Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
